| Literature DB >> 35087632 |
Umaru M Badaru1, Aliya M Hassan2, Rufai Y Ahmad1, Jibril M Nuhu1, Isa U Lawal1.
Abstract
INTRODUCTION: Sleep disturbance (SD) could have negative impact on the general well-being of children with cerebral palsy (CWCP).Entities:
Keywords: Cerebral Palsy; Exercise; Quality of Life; Sleep Deprivation
Year: 2021 PMID: 35087632 PMCID: PMC8776261 DOI: 10.5935/1984-0063.20200108
Source DB: PubMed Journal: Sleep Sci ISSN: 1984-0063
Common medications prescribed to the study participants.
| Name of Drug | Indication | Side Effects | Frequency (Percent) |
|---|---|---|---|
| Phenobarbitone | 10 (8.55) | ||
| Phenobarbitone + Encephabol | Anticonvulsant | Sedation and hypnosis | 9 (7.69) |
| Phenobarbitone + Carbamazepine | 2(1.71) | ||
| Carbamazepine | 7 (5.98) | ||
| Carbamazepine + Baclofen | Anticonvulsant | Sleepiness and drowsiness | 1(0.86) |
| Carbamazepine + Encephabol | 5(4.27) | ||
| Encephabol (Pyritinol) | 59(50.43) | ||
| Encephabol + diazepam | Nootropic, CNS activating | Insomnia | 1(0.86) |
| Encephabol + baclofen | 1(0.86) | ||
| Valproic Acid (VA) | 10(8.55) | ||
| VA + Baclofen VA + diazepam | anticonvulsant | Sleepiness, hypnosis and dry mouth | 1(0.86) 1(0.86) |
| VA + Encephabol | 4(3.42) | ||
| Baclofen | Antispastic | Sedation | 4(3.42) |
| Diazepam | Antispastic | Sleepiness | 1(0.86) |
| Benztropine | Anticholinergic/Anti-spasm | Drowsiness, dizziness and Dry mouth | 1(0.86) |
| Total | 117(100) |
CNS = central nervous system
Comparison of SD between CWCP and their Typically Developing Siblings.
| Variables | CWCP Mean ± SD | SIBLINGS Mean ± SD | U-value | Z-value | P-value |
|---|---|---|---|---|---|
| Overall SD score | 45.18±9.55 | 34±5.35 | 6447 | -11.73 | 0.001 |
| Frequency of pathologic SD | 63(31.5) | 0(0) | |||
| Disorders of initiation and maintaining sleep | 12.51 ± 4.35 | 8.47 ± 1.52 | 7581.50 | -10.87 | 0.000 |
| Frequency of pathologic SD | 42(21%) | 0(0%) | |||
| Sleep breathing disorders | 4.22 ± 1.86 | 3.54 ± 1.12 | 16270.50 | -3.93 | 0.000 |
| Frequency of pathologic SD | 33(16.5%) | 11(16.5%) | |||
| Disorders of arousal | 3.16 ± 0.57 | 3.29 ± 1.14 | 19853.00 | -0.267 | 0.790 |
| Frequency of pathologic SD | 4(2%) | 7(3.5%) | |||
| Sleep wake transition disorders | 10.92 ± 3.36 | 8.52 ± 2.20 | 11427.00 | -7.51 | 0.000 |
| Frequency of pathologic SD | 42(21%) | 5(2.5%) | |||
| Disorders of excessive somnolence | 10.27 ± 3.89 | 6.67 ± 2.02 | 8261.50 | -10.28 | 0.000 |
| Frequency of pathologic SD | 59(29.5%) | 2(1%) | |||
| Sleep hyperhidrosis | 4.24 ± 2.03 | 3.65 ± 1.87 | 16434.50 | -3.18 | 0.001 |
| Frequency of pathologic SD | 18(9%) | 13(6.5%) |
*significant; SD=sleep disturbance
Association between SD and each of medication use, clinical and demographic characteristics of the CWCP.
| Variables | SD category | Total (%) | χ2 | P-value | |
|---|---|---|---|---|---|
| Insignificant SD (%) | Pathologic SD (%) | ||||
|
| |||||
| Males | 83(60.6) | 35(55.6) | 118(59.0) | 0.451 | 0.502 |
| Females | 54(39.4) | 28(44.4) | 82(41.0) | ||
|
| |||||
| <4years | 70(51.1) | 33(52.4) | 103(51.5) | 0.029 | 0.880 |
| ≥4years | 67(48.9) | 30(47.6) | 97(48.5) | ||
|
| |||||
| Yes | 31(22.6) | 26(41.3) | 57(28.5) | 7.360 | 0.007* |
| No | 106(77.4) | 37(58.7) | 143(71.5) | ||
|
| |||||
| Quadriplegia | 46(33.6) | 23(36.5) | 69(34.5) | ||
| Diplegia | 7(5.1) | 4(6.3) | 11(5.5) | 3.452 | 0.485 |
| Hemiplegia | 57(41.6) | 29(46.0) | 86(43.0) | ||
| Monoplegia | 5(3.6) | 0(0) | 5(2.5) | ||
|
| 22(16.1) | 7(11.1) | 29(14.5) | ||
| No | 66(48.2) | 17(27.0) | 83(41.5) | 7.982 | 0.005* |
| Yes | 71(51.8) | 46(73.0) | 117(58.5) | ||
Key: *significant level, χ2 =chi square value, P=probability value, CP=cerebral palsy, Exra- pyramidal
Factors influencing SD among CWCP.
| Variables | Standardized coefficient (β) | P-value |
|---|---|---|
| GMFCS | 0.39 | 0.000* |
| Medication | 0.09 | 0.21 |
| Age | -0.02 | 0.78 |
| Gender | 0.15 | 0.02* |
| BMI | 0.05 | 0.56 |
| Type of CP | -0.03 | 0.78 |
| Hamstrings spasticity | -0.04 | 0.75 |
| Biceps spasticity | 0.00 | 0.99 |
| Hip adductor spasticity | -0.04 | 0.73 |
| Epilepsy | -0.13 | 0.08 |
Factors Influencing the Quality of Life of CWCP.
| Variables | P-Value model 1 | P-Value model 1 | Standardized Coefficient Beta Model 2 | R square | R square Change | F-Value | P-value | |
|---|---|---|---|---|---|---|---|---|
| Age | 0.001* | 0.001* | -0.207 | |||||
| Gender | 0.538 | 0.279 | 0.055 | |||||
| BM1 | 0.735 | 0.612 | 0.030 | |||||
| CP type | 0.977 | 0.932 | -0.007 | |||||
| Hamstrings SP | 0.013* | 0.008* | -0.250 | 0.539 | 0.539 | 20.224 | 0.001* | |
| Biceps SP | 0.381 | 0.398 | -0.084 | |||||
| Confounding variables | Hip Adductors SP | 0.114 | 0.132 | 0.128 | ||||
| Epilepsy | 0.934 | 0.607 | -0.028 | |||||
| Medication | 0.542 | 0.724 | -0.020 | |||||
| GMFCS | 0.000* | 0.000* | -0.505 | |||||
| Predictor Variable | Sleep disturbance | 0.001* | 0.001* | -0.177 | 0.565 | 0.020 |
Key: Dependent variable=quality of life; Model 1=before control; model 2=after control; SP=spasticity; CP= cerebral palsy, P=probability level, *= significant.
Influence of SD on Active Home-Based Exercise Participation.
| Variables | P-Value model 1 | P-Value model 2 | Standardized Coefficient Beta Model 2 | R square | R square Change | Repression df | Residual df | F value | P-value | |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | 0.002* | 0.001* | -0.209 | |||||||
| Epilepsy | 0.042* | 0.101 | 0.102 | |||||||
| GMFCS | 0.003* | 0.097 | -0.116 | |||||||
| Hamstrings | 0.971 | 0.985 | -0.002 | 0.370 | 0.370 | 9 | 199 | 12.42* | 0.000 | |
| Confounding | Biceps | 0.456 | 0.461 | 0.080 | ||||||
| Hip adductors | 0.971 | 0.901 | -0.012 | |||||||
| Cp type | 0.520 | 0465 | 0.057 | |||||||
| Medication | 0.000* | 0.000* | -0.395 | |||||||
| Gender | 0.741 | 0.363 | 0.053 | |||||||
| Predictor variable | Sleep disturbance | 0.000* | 0.000* | -0.225 | 0.411 | 0.041 |
Key: Dependent variable = Active home exercise participation, * significant, Model 1=before control; model 2=after control
Influence of SD on Active Clinic-based Exercise Participation.
| Variables | P-Value model 1 | P-Value model 2 | Standardized Coefficient Beta Model 2 | R square | R square Change | Repression DF | Residual DF | F value | P-value | |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | 0.005* | 0.002* | -0.190 | |||||||
| Epilepsy | 0.010* | 0.029* | 0.135 | |||||||
| GMFCS | 0.007* | 0.173 | -0.095 | |||||||
| Hamstring | 0.912 | 0.956 | 0.006 | 0.370 | 0.370 | 9 | 190 | 12.41 | 0.00* | |
| Biceps | 0.689 | 0.704 | 0.041 | |||||||
|
| Hip adductors | 0.912 | 0.982 | 0.002 | ||||||
| Gender | 0.935 | 0.493 | 0.040 | |||||||
| Medication | 0.000* | 0.000* | -0.389 | |||||||
| Cp type | 0.645 | 0.583 | 0.43 | |||||||
|
| Sleep disturbance | 0.000* | 0.000* | -0.236 | 0.415 | 0.045 |
Dependent variable = Active clinic exercise participation *significant, Model 1=before control; model 2=after control